S110 Efficacy and safety of nintedanib in patients with IPF beyond week 52: Data from the Phase II TOMORROW trial | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Spoken sessions

Nintedanib or pirfenidone?

S110 Efficacy and safety of nintedanib in patients with IPF beyond week 52: Data from the Phase II TOMORROW trial

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Richeldi L, Costabel U, Selman M, et al

S110 Efficacy and safety of nintedanib in patients with IPF beyond week 52: Data from the Phase II TOMORROW trial

Thorax 2015;70:A63-A64.